[
  {
    "ts": null,
    "headline": "US corporate debt market returns in force after market holiday",
    "summary": "At least 27 issuers tapped the high-grade corporate bond market on Tuesday, according to market participants -- the first day of the Labor Day holiday-shortened week that is historically the busiest of the year for high-grade bond market deal-making.  American pharmaceutical company Merck turned to the bond market for $5 billion to help fund its $10 billion buyout of peer Verona Pharma announced on July 9.  All told, Tuesday tallied at least $40.8 billion in high-grade corporate bond sales at market close, according to Hans Mikkelsen, managing director of credit strategy at TD Securities.",
    "url": "https://finnhub.io/api/news?id=900a64a5da236140d0e92beb85978677e9cbe5d2b7610b54fceb2a23234d334f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756913234,
      "headline": "US corporate debt market returns in force after market holiday",
      "id": 136615727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "At least 27 issuers tapped the high-grade corporate bond market on Tuesday, according to market participants -- the first day of the Labor Day holiday-shortened week that is historically the busiest of the year for high-grade bond market deal-making.  American pharmaceutical company Merck turned to the bond market for $5 billion to help fund its $10 billion buyout of peer Verona Pharma announced on July 9.  All told, Tuesday tallied at least $40.8 billion in high-grade corporate bond sales at market close, according to Hans Mikkelsen, managing director of credit strategy at TD Securities.",
      "url": "https://finnhub.io/api/news?id=900a64a5da236140d0e92beb85978677e9cbe5d2b7610b54fceb2a23234d334f"
    }
  },
  {
    "ts": null,
    "headline": "MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline",
    "summary": "Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.",
    "url": "https://finnhub.io/api/news?id=da90ce74accb39b2cf77d3534087268569b5ed028ee8305c6af395eaa031b6ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756912020,
      "headline": "MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline",
      "id": 136616933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.",
      "url": "https://finnhub.io/api/news?id=da90ce74accb39b2cf77d3534087268569b5ed028ee8305c6af395eaa031b6ea"
    }
  },
  {
    "ts": null,
    "headline": "J&J Gears Up for Some Key New Drug Approvals and Launches",
    "summary": "JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.",
    "url": "https://finnhub.io/api/news?id=a8a5730ba2e501e9314437e189fcd95d6828f4c15c021bbf80055f56dfbe0a9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756911840,
      "headline": "J&J Gears Up for Some Key New Drug Approvals and Launches",
      "id": 136616897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.",
      "url": "https://finnhub.io/api/news?id=a8a5730ba2e501e9314437e189fcd95d6828f4c15c021bbf80055f56dfbe0a9c"
    }
  }
]